Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The tumor suppressor protein p53, or "guardian of the genome," is frequently mutated in human cancers.
• Mutant p53 acquires oncogenic properties distinct from wild-type p53, complicating targeted therapies.
• Existing therapeutic strategies targeting mutant p53 have shown limited clinical success.

Purpose of the Study:

• To review current therapeutic strategies targeting the p53 pathway in cancer.
• To explore novel approaches for overcoming challenges associated with p53 mutations in cancer treatment.
• To evaluate the potential of bypassing p53 as a therapeutic avenue.

Main Methods:

• Review of existing literature on p53-targeted cancer therapies.
• Classification of emerging therapeutic agents targeting mutant p53 into six categories.
• Analysis of the limitations and potential of current and future p53-targeting strategies.

Main Results:

• Despite decades of research, targeting p53 has faced significant clinical barriers due to mutation heterogeneity and oncogenic gain-of-function.
• Several classes of agents targeting mutant p53 have been developed, including viral therapies, direct/epigenetic modifiers, synthetic lethals, reactivators, and vaccines.
• These advanced strategies have also encountered limited efficacy, highlighting the need for alternative approaches.

Conclusions:

• Targeting mutant p53 remains a significant challenge in cancer therapy.
• Bypassing the p53 pathway altogether presents a promising alternative for developing novel cancer treatments.
• Future therapeutic strategies may focus on tumor cell killing mechanisms independent of p53 status.